Vaiomer

Executive Summary

Vaiomer is a French biotechnology company founded in 2011 that has established itself as a pioneer and leader in the analysis of low bacterial biomass microbiomes, particularly in blood and tissues. The company's contamination-aware metagenomic services enable reliable exploration of systemic and tissue-resident microbiota, supporting research into disease mechanisms, biomarker discovery, and therapeutic target identification across a wide range of health conditions. By addressing the technical challenges of analyzing low-biomass samples, Vaiomer occupies a unique niche in the microbiome field, which has traditionally focused on high-biomass environments like the gut. The company's expertise positions it as a key partner for pharmaceutical and academic researchers seeking to understand the role of microbiota in diseases such as cancer, metabolic disorders, and inflammatory conditions. With a strong foothold in France and growing global interest in the microbiome's impact on health, Vaiomer is well-positioned to expand its service offerings and collaborations, potentially driving revenue growth and strategic partnerships. However, as a private company with limited public financial disclosures, the conviction in its near-term valuation growth is moderate, pending clearer commercialization milestones.

Upcoming Catalysts (preview)

• Q4 2026Announcement of major pharma partnership for systemic microbiome analysis40% success
• TBDExpansion of service portfolio to include single-cell microbiome analysis30% success
• H1 2027Series B funding round to scale commercial operations50% success